Quest Diagnostics integrates cancer tests into Flatiron's OncoEMR platform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St set for lower open as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges higher against euro
Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI
July 8, 2026 8:52 AM EDTAmerican Oncology Network (AON) and other community oncology providers launching now as part of a pilot program that provides access to Haystack MRD
SECAUCUS, N.J., July 8, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it is integrating its Haystack MRD® ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers within OncoEMR®, an electronic health record (EHR) from... More
